Xeris Biopharma Achieves First Net Income, Reports Strong Revenue Growth, and Advances Key Pipeline Asset
XERS sits 67% above its 52-week low of $3.59 on elevated volume (2.4× avg).
Summary
Xeris Biopharma reported its first net income in 2025, with strong revenue growth and positive operating cash flow, while advancing a key pipeline asset and navigating patent litigation for its lead product.
Key Events · Earnings and Guidance · XERS
-
First-Ever Net Income Achieved
Xeris Biopharma reported net income of $0.6 million for the fiscal year ended December 31, 2025, marking its first profitable year since inception, a significant improvement from net losses of $54.8 million in 2024.
-
Strong Revenue Growth
Total revenue increased by 43.7% to $291.8 million in 2025 from $203.1 million in 2024, primarily driven by a 116.7% increase in Recorlev net revenue due to higher patient demand.
-
Positive Operating Cash Flow
The company generated $28.6 million in net cash from operating activities for the year ended December 31, 2025, a substantial turnaround from using $37.0 million in 2024.
-
XP-8121 Pipeline Advances to Phase 3
The XP-8121 (once-weekly subcutaneous levothyroxine) product candidate is now Phase 3-ready, with a clinical trial planned for 2026, targeting a substantial estimated market opportunity of $1.0 to $3.0 billion in peak net sales.
Analysis · XERS · Life Sciences
Xeris Biopharma Holdings, Inc. reported its first-ever net income of $0.6 million for the fiscal year ended December 31, 2025, a significant turnaround from prior losses. This financial improvement was driven by robust product revenue growth, particularly from Recorlev, and a shift to positive operating cash flow. The company also advanced its XP-8121 pipeline candidate to Phase 3, with a clinical trial planned for 2026. While the company is engaged in patent infringement litigation for Recorlev, the filing of the lawsuit triggered a 30-month stay on generic FDA approval, providing temporary market exclusivity. Investors should monitor the outcome of this litigation and the commercialization progress of XP-8121.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.5% of the 1531 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XERS was trading at $6.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $998.9M. The 52-week trading range was $3.59 to $10.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.